Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Aggressive hypertension, diabetes management programmes to curb CVD in Singapore

Tristan Manalac
24 Aug 2019
Looking into 2018, Singapore has a few plans in mind to improve healthcare for the public, especially the elderly.

Aggressive population-level management programmes targeting hypertension and diabetes may help curtail the rise of cardiovascular diseases (CVD) and associated deaths and disabilities in Singapore, according to a recent study.

Accessing publicly available sets of data from the Ministry of Health, researchers created simulation models that determined the effect of aggressive hypertension, diabetes and smoking cessation management interventions on the incidence and outcomes of CVD. The model used underwent consultations with expert clinicians and was verified using the current available evidence and knowledge about CVD.

From 369,133 cases in 2010, diabetes in Singapore was projected to balloon by 142 percent, reaching a peak of 893,412 cases by 2040. A similar pattern was observed for hypertension, which was predicted to grow by 61.6 percent, from 659,958 in 2010 to 1,067,048 by 2040. These changes can be explained by Singapore’s ageing population and changes in their lifestyles. [BMC Public Health 2019;19:1105]

Concurrently, the number of adult smokers (aged 18 years) was also expected increase by 17 percent, from 414,789 in 2010 to 485,524 by 2040.

Under these circumstances, the incidence of CVD in Singapore was likewise projected to multiply from 33,292 cases in 2010 to 86,592 by 2040. Over the same time period, the age-adjusted incidence rate of CVD was estimated to grow from 0.88 percent to 1.84 percent.

Similarly, deaths due to CVD were projected to increase from 5,329 to 14,714 from 2010 to 2040, corresponding to a 176-percent increase.

In the presence of a strict diabetes management programme, the model―which operated under the assumption that more individuals would have had managed diabetes―estimated a total of 75,647 CVD events by 2040. This was a 12.6-percent reduction compared with the base-case scenario. The number of CVD-related deaths, likewise, was expected to be decreased by 5.7 percent.

In comparison, an aggressive hypertension management programme resulted in a total of 79.812 CVD cases by 2040, corresponding to a 7.8-percent decline relative to base-case numbers. CVD deaths were likewise reduced by 3.9 percent. Similar effects were observed when a strict smoking cessation programme was included in the base model, though to a lesser extent.

When all three aggressive programmes were put in place, the total number of CVD events and CVD deaths by 2040 dropped by 24 percent and 12.2 percent, respectively, as compared to the base-case scenario.

“The findings from this research synthesize data from a variety of sources and suggest that CVD events and associated deaths and disabilities could be reduced significantly if diabetes and hypertension patients are aggressively managed,” said researchers.

“Although health policy in Singapore is increasing emphasis on the prevention and management of chronic conditions, a recent noble policy that declared a war on diabetes should be expanded to include a war on hypertension in order to fully benefit from the combined impact of diabetes and hypertension management,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.